Medicine RSS Search Engine

Cilostazol Cilostazol RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

This page shows you the latest news and research items in this category.

Pharmacological treatment and therapeutic perspectives of metabolic syndrome
Abstract Metabolic syndrome is a disorder based on insulin resistance. Metabolic syndrome is diagnosed by a co-occurrence of three out of five of the following medical conditions: abdominal obesity, elevated blood pressures, elevated glucose, high triglycerides, and low high-density lipoprotein-cholesterol (HDL-C) levels. Clinical implication of metabolic syndrome is that it increases the risk of developing type 2 diabetes and cardiovascular diseases. Prevalence of the metabolic syndrome has increased globally, particularly in the last decade, to the point of being regarded as an epidemic. The prevalence of metabo...
Source: Reviews in Endocrine and Metabolic Disorders - October 23, 2014 Category: Endocrinology Source Type: research

Colonic diverticular hemorrhage associated with the use of nonsteroidal anti‐inflammatory drugs, low‐dose aspirin, antiplatelet drugs, and dual therapy
ConclusionsBesides alcohol and smoking, NSAIDs, low‐dose aspirin, and antiplatelet drugs are risk factors for diverticular bleeding. The magnitude of risk may differ between different kinds of NSAIDs and antiplatelet drugs, and dual therapy with NSAIDs or antiplatelet drugs increases the risk of bleeding. (Source: Journal of Gastroenterology and Hepatology)
Source: Journal of Gastroenterology and Hepatology - October 15, 2014 Category: Gastroenterology Authors: Naoyoshi Nagata, Ryota Niikura, Tomonori Aoki, Takuro Shimbo, Yoshihiro Kishida, Katsunori Sekine, Shohei Tanaka, Kazuhiro Watanabe, Toshiyuki Sakurai, Chizu Yokoi, Junichi Akiyama, Mikio Yanase, Masashi Mizokami, Naomi Uemura Tags: Gastroenterology Source Type: research

GW25-e4606 Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials
(Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 13, 2014 Category: Radiology Source Type: research

GW25-e4213 Acute and chronic effects of cilostazol on transient outward potassium current in isolated rat right ventricular myocytes
(Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - October 13, 2014 Category: Radiology Source Type: research

Inhibitors of PDE4, but Not PDE3, Increase β2-agonist-induced Expression of Anti-inflammatory MKP-1 in Airway Smooth Muscle Cells.
Abstract β2-agonists are principally used in asthma to provide bronchodilation, however they also have anti-inflammatory properties due, in part, to their ability to upregulate mitogen-activated protein kinase phosphatase 1 (MKP-1) in a cAMP-dependent manner. Phosphodiesterases (PDEs) are attractive targets for potentiating the anti-inflammatory response. There are 11 subfamilies of PDE enzymes, among these, inhibition of PDE3 and PDE4 are the main targets for airway smooth muscle (ASM). PDE enzymes are important intracellular regulators that catalyze the breakdown of cAMP and/or cGMP to their inactive forms. Give...
Source: American Journal of Respiratory Cell and Molecular Biology - October 8, 2014 Category: Molecular Biology Authors: Patel BS, Prabhala P, Oliver BG, Ammit AJ Tags: Am J Respir Cell Mol Biol Source Type: research

The phosphodiesterase 3 inhibitor cilostazol does not stimulate growth of colorectal liver metastases after major hepatectomy
Abstract Liver failure after extended hepatectomy represents a major challenge in the surgery of hepatic colorectal metastasis. A previous study has indicated that inhibition of phosphodiesterase type 3 (PDE 3) stimulates liver regeneration. However, little is known whether PDE 3 inhibitors, such as cilostazol, also stimulate the growth of remnant metastases. Therefore, we herein studied the effect of cilostazol on engraftment, vascularization and growth of colorectal liver metastasis after major hepatectomy. WAG-rats underwent either major hepatectomy or sham operation. Metastases were induced by subcapsular imp...
Source: Clinical and Experimental Metastasis - October 1, 2014 Category: Cancer & Oncology Source Type: research

Diabetes augments cognitive dysfunction in chronic cerebral hypoperfusion by increasing neuronal cell death: Implication of cilostazol for diabetes mellitus-induced dementia.
In conclusion, diabetes can aggravate cognitive dysfunction in vascular dementia, and PDE-3 inhibitors, such as cilostazol, may form the basis of a novel therapeutic strategy for diabetes-associated cognitive impairment or vascular dementia. PMID: 25281785 [PubMed - as supplied by publisher] (Source: Neurobiology of Disease)
Source: Neurobiology of Disease - October 1, 2014 Category: Neurology Authors: Kwon KJ, Lee EJ, Kim MK, Kim SY, Kim JN, Kim JO, Kim HJ, Kim HY, Han JS, Shin CY, Han SH Tags: Neurobiol Dis Source Type: research

Clinical management of esophagogastroduodenoscopy by clinicians under the former guidelines of the Japan Gastroenterological Endoscopy Society for patients taking anticoagulant and antiplatelet medications
Conclusion We revealed the low impact of the 2005 JGES guidelines on the management of antithrombotic drugs. Our physicians have reasonably decided to continue antithrombotic drugs before EGD according to the risk of thromboembolism. (Source: Gastric Cancer)
Source: Gastric Cancer - September 25, 2014 Category: Gastroenterology Source Type: research

PTEN Upregulation May Explain the Development of Insulin Resistance and Type 2 Diabetes with High Dose Statins
Conclusions Long-term ROS can induce diabetes by upregulating PTEN. CIL attenuates these changes. Partial knockdown of PTEN also ameliorates ROS-induced insulin resistance. Further studies are needed to assess the effects of increasing cAMP levels to prevent the induction of diabetes by statins. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - September 25, 2014 Category: Cardiology Source Type: research

EHMTI-0033. The phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cAMP increase
(Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - September 18, 2014 Category: Neurology Source Type: research

The Phosphodiesterase III Inhibitor Cilostazol Ameliorates Ethanol-Induced Endothelial Dysfunction.
Abstract Intracranial hemorrhage (ICH) remains a devastating disease, and heavy alcohol consumption is an underlying risk factor. The aim of this study was to study the mechanism of ethanol-induced endothelial cell damage and to evaluate the protective effect of cilostazol against ethanol-induced damage. We first evaluated transendothelial electrical resistance (TEER) and cell viability of human brain microvascular endothelial cells at the ethanol concentration shown to cause mild-to-moderate intoxication in the clinic. We also assessed the permeability of fluorescein isothiocyanate (FITC)-dextran and the change in...
Source: Current Neurovascular Research - September 12, 2014 Category: Neurology Authors: Takagi T, Mishiro K, Shimazawa M, Yoshimura S, Iwama T, Hara H Tags: Curr Neurovasc Res Source Type: research

Efficacy of two different self-expanding nitinol stents for atherosclerotic femoropopliteal arterial disease (SENS-FP trial): study protocol for a randomized controlled trial
DiscussionThis trial will provide powerful insight into whether the design of the COMPLETETM-SE stent is more fracture-resistant or effective in preventing restenosis compared with the SMARTTM CONTROL stent. Also, it will determine the efficacy and safety of aspirin plus clopidogrel versus aspirin plus cilostazol in patients undergoing stent implantation in femoropopliteal lesions.Trial registration: Registered on 2 April 2012 with the National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier# NCT01570803). (Source: Trials)
Source: Trials - September 10, 2014 Category: Journals (General) Authors: Sang ParkSeung RhaCheol ChoiEung KimDong OhYun ChoWoong ChoiSeung LeeYong KimSeung ChoiWon KimKi KimJang ChoJoo KimSang KimJang BaeJung BongWon KangJu BaekJae SeoWoo ChungMahn ParkSung HerJon SuhMin KimYeo KimHwan ChoiJae Soh Source Type: research

A randomised, multicentre, double blind, placebo controlled trial to evaluate the efficacy and safety of cilostazol in patients with vasospastic angina
Conclusions Cilostazol is an effective therapy for patients with VSA uncontrolled by conventional amlodipine therapy, and has no serious side effects. Trial registration number NCT01444885. (Source: Heart)
Source: Heart - September 9, 2014 Category: Cardiology Authors: Shin, E.-S., Lee, J.-H., Yoo, S.-Y., Park, Y., Hong, Y. J., Kim, M. H., Lee, J.-Y., Nam, C.-W., Tahk, S.-J., Kim, J.-S., Jeong, Y.-H., Lee, C. W., Shin, H. K., Kim, J.-H. Tags: Coronary artery disease Source Type: research

Disintegration Mediated Controlled Release Supersaturating Solid Dispersion Formulation of an Insoluble Drug: Design, Development, Optimization, and In Vitro Evaluation.
The objective of this study was to develop a solid dispersion based controlled release system for drug substances that are poorly soluble in water. A wax-based disintegration mediated controlled release system was designed based on the fact that an amorphous drug can crystallize out from hydrophilic matrices. For this study, cilostazol (CIL) was selected as the model drug, as it exhibits poor aqueous solubility. An amorphous solid dispersion was prepared to assist the drug to attain a supersaturated state. Povidone was used as carrier for solid dispersion (spray drying technique), hydrogenated vegetable oil (HVO) as wax ma...
Source: AAPS PharmSciTech - September 5, 2014 Category: Drugs & Pharmacology Authors: Verma S, Rudraraju VS Tags: AAPS PharmSciTech Source Type: research

Renexin as a rescue regimen for noise-induced hearing loss.
This study was designed to investigate the protective effects of renexin on hearing, the organ of Corti (OC), and medial olivocochlear efferents against noise-induced damage. C57BL/6 mice were exposed to 110 dB SPL white noise for 60 min and then randomly divided into three groups: high- and low-dose renexin-treated groups and noise only group. Renexin were administered for 7 days: 90 mg/kg to the low-dose, and 180 mg/kg to the high-dose groups. All mice, including the controls underwent hearing tests on postnoise day 8 and were killed for cochlear harvest. We compared the hearing thresholds and morphology of the OC and co...
Source: Noise and Health - September 1, 2014 Category: Audiology Authors: Park SY, Back SA, Kim HL, Kim DK, Yeo SW, Park SN Tags: Noise Health Source Type: research

Carotid Plaque Characteristics on Magnetic Resonance Plaque Imaging Following Long-term Cilostazol Therapy
Conclusions: Signal alterations on MR plaque imaging indicated the increase of fibrous components and the decrease of lipid/necrotic components in the carotid plaque during the cilostazol therapy. (Source: Journal of Stroke and Cerebrovascular Diseases)
Source: Journal of Stroke and Cerebrovascular Diseases - August 29, 2014 Category: Neurology Authors: Mao Yamaguchi Oura, Makoto Sasaki, Hideki Ohba, Shinsuke Narumi, Kazumasa Oura, Ikuko Uwano, Yasuo Terayama Tags: Original Articles Source Type: research

Induction of heme oxygenase‑1 expression protects articular chondrocytes against cilostazol‑induced cellular senescence.
Abstract Chondrocyte senescence is associated with the aging and degeneration of cartilage, and eventually leads to joint destruction. The aim of this study was to elucidate the mechanisms responsible for the cytoprotective effects of heme oxygenase‑1 (HO‑1) on chondrocytes in cartilage. Chondrocyte senescence was induced using cilostazol and measured using a specific senescence‑associated β‑galactosidase (SA‑β‑gal) staining assay. Cilostazol altered the expression of type Ⅱ collagen and β‑catenin, which are phenotypic markers of the differentiation and dedifferentiation of chondrocytes. Cilos...
Source: International Journal of Molecular Medicine - August 29, 2014 Category: Molecular Biology Authors: Kim KM, Park SE, Lee MS, Kim K, Park YC Tags: Int J Mol Med Source Type: research

Phosphodiesterase Inhibitors as a Target for Cognition Enhancement in Aging and Alzheimer's Disease: a Translational Overview.
Abstract Phosphodiesterase inhibitors (PDE-Is) enhance cAMP and/or cGMP signaling via reducing the degradation of these cyclic nucleotides. Since both cAMP and cGMP signaling are essential in a variety of cellular functions, including neuroplasticity and neuroprotection, PDE-Is are receiving increased attention as possible targets for treatment of age-related cognitive decline as well as Alzheimer's disease (AD). In this review we will give a translational overview of the preclinical and clinical data on PDE-Is and cognition enhancement focusing on aging and AD. PDE2, 4 and 5 inhibitors improved memory performance ...
Source: Current Pharmaceutical Design - August 26, 2014 Category: Drugs & Pharmacology Authors: Heckman PR, Wouters C, Prickaerts J Tags: Curr Pharm Des Source Type: research

Beneficial effect of cilostazol‐mediated neuronal repair following trimethyltin‐induced neuronal loss in the dentate gyrus
Cilostazol acts as an antiplatelet agent and has other pleiotropic effects based on phosphodiesterase‐3‐dependent mechanisms. We evaluated whether cilostazol would have a beneficial effect on neuronal repair following hippocampal neuronal damage by using a mouse model of trimethyltin (TMT)‐induced neuronal loss/self‐repair in the hippocampal dentate gyrus [Ogita et al. (2005) J Neurosci Res 82:609−621]; these mice will hereafter be referred to as impaired animals. A single treatment with cilostazol (10 mg/kg, i.p.) produced no significant change in the number of 5‐bromo‐2′‐deoxyuridine (BrdU)‐incorporat...
Source: Journal of Neuroscience Research - August 20, 2014 Category: Neuroscience Authors: Masanori Yoneyama, Masayuki Tanaka, Shigeru Hasebe, Taro Yamaguchi, Tatsuo Shiba, Kiyokazu Ogita Tags: Research Article Source Type: research

CILOSTAZOL Tablet [Carilion Materials Management]
Updated Date: Aug 15, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 15, 2014 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [American Health Packaging]
Updated Date: Aug 11, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - August 11, 2014 Category: Drugs & Pharmacology Source Type: news

CILOSTAZOL Tablet [Preferred Pharmaceuticals, Inc.]
Updated Date: Jul 31, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 31, 2014 Category: Drugs & Pharmacology Source Type: news

Donepezil Can Improve Ischemic Muscle Atrophy by Activating Angiomyogenic Properties of Satellite Cells.
Conclusions:The present results suggest that a clinical dosage of DPZ accelerates angiomyogenesis by directly acting on both endothelial and satellite cells. Therefore, DPZ is a potential additional choice for conventional drug therapy against PAD. PMID: 25070503 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - July 25, 2014 Category: Cardiology Authors: Noguchi T, Kakinuma Y, Arikawa M, Okazaki K, Hoshino E, Iiyama T, Kubo T, Kitaoka H, Doi Y, Sato T Tags: Circ J Source Type: research

CILOSTAZOL Tablet [Teva Pharmaceuticals USA Inc]
Updated Date: Jul 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - July 24, 2014 Category: Drugs & Pharmacology Source Type: news

The phosphodiesterase 3 inhibitor cilostazol does not stimulate growth of colorectal liver metastases after major hepatectomy.
Abstract Liver failure after extended hepatectomy represents a major challenge in the surgery of hepatic colorectal metastasis. A previous study has indicated that inhibition of phosphodiesterase type 3 (PDE 3) stimulates liver regeneration. However, little is known whether PDE 3 inhibitors, such as cilostazol, also stimulate the growth of remnant metastases. Therefore, we herein studied the effect of cilostazol on engraftment, vascularization and growth of colorectal liver metastasis after major hepatectomy. WAG-rats underwent either major hepatectomy or sham operation. Metastases were induced by subcapsular impla...
Source: Clinical Colorectal Cancer - July 23, 2014 Category: Cancer & Oncology Authors: Strowitzki MJ, Dold S, von Heesen M, Körbel C, Scheuer C, Moussavian MR, Schilling MK, Kollmar O, Menger MD Tags: Clin Exp Metastasis Source Type: research

Cilostazol prevents the degradation of collagen Type II in human chondrocytes.
In this study, we reported that cilostazol is able to suppress the degradation of type II collagen in human chondrocytes induced by IL-1β. Mechanistically, cilostazol treatment leads to inhibiting the expression of IRF-1, thereby prevents the induction of MMP-13. Signal transducers and activator of transcription 1 (STAT1) has been reported to play an essential role in regulating the activation of IRF-1. Our results indicated that cilostazol suppresses the activation of STAT1 by mitigating the phosphorylation of STAT1 at Ser727 and tyrosine phosphorylation of STAT1 at position 701 (Tyr701). PMID: 25044117 [PubMed - as ...
Source: Biochemical and Biophysical Research communications - July 17, 2014 Category: Biochemistry Authors: Wang W, Kang W, Tang Q, Yao G, Chen Y, Cheng B, Kong K Tags: Biochem Biophys Res Commun Source Type: research

The Limits of Evidence in Drug Approval and Availability: A Case Study of Cilostazol and Naftidrofuryl for the Treatment of Intermittent Claudication.
This article provides an overview of the pharmacology of cilostazol and naftidrofuryl, and the clinical studies leading to their approval and clinical acceptance. It further explores the possible sources of bias in analyzing these clinical trials, some of which have been brought to light by the National Institute for Health and Clinical Excellence (NICE) of the United Kingdom in its technology appraisal guidance. It also speculates the ways in which economic incentives may affect drug-marketing decisions. METHODS: A literature review of pharmacology and clinical trials for cilostazol and naftidrofuryl was performed in ...
Source: Clinical Therapeutics - July 7, 2014 Category: Drugs & Pharmacology Authors: Hong H, Mackey WC Tags: Clin Ther Source Type: research

Do the Antithrombotic Therapy at the Time of Intracerebral Hemorrhage Influence Clinical Outcome? Analysis between the Difference of Antiplatelet and Anticoagulant Agents and Clinical Course
Background: It is controversial whether taking antiplatelet agents (APs) or anticoagulant agents (ACs) could influence clinical outcome after intracerebral hemorrhage (ICH).Methods: We retrospectively investigated 557 ICH patients between September 2008 and August 2013. We reviewed patients' characteristics, hematoma volume, deterioration (hematoma expansion, surgical hematoma evacuation, or death), and clinical outcome in modified Rankin Scale.Results: A total of 397 were classified as neither AP nor AC (“Nothing”), 81 as single AP (44 as aspirin [ASA], 22 as clopidogrel or ticlopidine [CLP/TIC], 7 as cilostazol, 8 as...
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Takeshi Okada, Taizen Nakase, Masahiro Sasaki, Tatsuya Ishikawa Tags: Original Articles Source Type: research

Healthcare Quality Indicators of Peripheral Artery Disease Based on Systematic Reviews
Conclusions: These quality indicators will help clinicians to assess the appropriateness of healthcare provided in PAD. The development of evidence-based indicators in PAD is limited by the lack of methodological quality of the research in this disease, the inconclusiveness of the evidence on diagnostic and surgical techniques, and the dynamic nature of the vascular diseases field. (Source: European Journal of Vascular and Endovascular Surgery)
Source: European Journal of Vascular and Endovascular Surgery - June 16, 2014 Category: Surgery Authors: S. Bellmunt, M. Roqué, D. Osorio, H. Pardo, J.-R. Escudero, X. Bonfill Tags: Peripheral Arterial Disease Source Type: research

Cilostazol and outcome in outpatients with peripheral artery disease
(Source: Thrombosis Research)
Source: Thrombosis Research - June 5, 2014 Category: Hematology Authors: Paulina Perez, Carlos Esteban, Joan Carles Sauquillo, Monserrat Yeste, Luis Manzano, Abel Mujal, Pedro Enrique Jiménez Caballero, Eduardo Aguilar, Juan Francisco Sánchez Muñoz-Torrero, Manuel Monreal, the FRENA Investigators Source Type: research

Cilostazol suppresses β‐amyloid production by activating a disintegrin and metalloproteinase 10 via the upregulation of SIRT1‐coupled retinoic acid receptor‐β
In conclusion, cilostazol suppresses the accumulations of FL‐APP and Aβ by activating ADAM10 via the upregulation of SIRT1‐coupled RARβ. © 2014 Wiley Periodicals, Inc. (Source: Journal of Neuroscience Research)
Source: Journal of Neuroscience Research - June 5, 2014 Category: Neuroscience Authors: Hye Rin Lee, Hwa Kyoung Shin, So Youn Park, Hye Young Kim, Won Suk Lee, Byung Yong Rhim, Ki Whan Hong, Chi Dae Kim Tags: Research Article Source Type: research

Surgeon Still a Step Behind Medicine: Indicators of Healthcare for Peripheral Artery Disease
Patients with peripheral arterial disease (PAD) currently have a range of therapies that might improve outcomes, including supervised exercise programs, medications, endovascular procedures, and surgery. An appropriate clinical approach to PAD could decrease morbidity and mortality, reduce the risk of amputation, and increase patients' functional status and quality of life. Nevertheless, in clinical practice significant judgment by the physician to adapt the variety of treatments available to the care of each individual patient with PAD is often required with uncertain and often unsatisfactory effects on outcomes. Even tho...
Source: European Journal of Vascular and Endovascular Surgery - May 22, 2014 Category: Surgery Authors: P. De Rango Tags: Invited Commentary Source Type: research

Abnormal Repolarization as the Basis for Late Potentials and Fractionated Electrograms Recorded From Epicardium in Experimental Models of Brugada Syndrome
ConclusionsThese data point to an alternative pathophysiological basis for late potentials and fractionated electrical activity recorded in the right ventricle in the setting of BrS. We demonstrate an association of such activity with abnormal repolarization and not with abnormal depolarization or structural abnormalities. (Source: Journal of the American College of Cardiology: Cardiovascular Interventions)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - May 12, 2014 Category: Cardiology Source Type: research

Three types of ependymal cells with intracellular calcium oscillation are characterized by distinct cilia beating properties
Ependymal cells are multiciliated epithelial cells that line the ventricles in the adult brain. Abnormal function or structure of ependymal cilia has been associated with various neurological deficits. For the first time, we report three distinct ependymal cell types, I, II, and III, based on their unique ciliary beating frequency and beating angle. These ependymal cells have specific localizations within the third ventricle of the mouse brain. Furthermore, neither ependymal cell types nor their localizations are altered by aging. Our high‐speed fluorescence imaging analysis reveals that these ependymal cells have an int...
Source: Journal of Neuroscience Research - May 10, 2014 Category: Neuroscience Authors: Tongyu Liu, Xingjian Jin, Rahul M. Prasad, Youssef Sari, Surya M. Nauli Tags: Research Article Source Type: research

Combination therapy of cilostazol and bepridil suppresses recurrent ventricular fibrillation related to J-wave syndromes
(Source: Heart Rhythm)
Source: Heart Rhythm - May 6, 2014 Category: Cardiology Authors: Tetsuji Shinohara, Yuki Ebata, Reika Ayabe, Akira Fukui, Norihiro Okada, Kunio Yufu, Mikiko Nakagawa, Naohiko Takahashi Source Type: research

Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics
ConclusionEndoscopic biopsy did not increase the bleeding risk despite not stopping antithrombotics prior to biopsy even among patients taking warfarin whose PT‐INR was within the therapeutic range. (Source: Digestive Endoscopy)
Source: Digestive Endoscopy - April 28, 2014 Category: Gastroenterology Authors: Minoru Fujita, Akiko Shiotani, Takahisa Murao, Manabu Ishii, Yoshiyuki Yamanaka, Rui Nakato, Hiroshi Matsumoto, Ken‐ichi Tarumi, Noriaki Manabe, Tomoari Kamada, Jiro Hata, Ken Haruma Tags: Original Article Source Type: research

Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy
Conclusion: The results of the present study highlight that clopidogrel and cilostazol combination therapy may be considered to be an alternative method for treating patients with CLI unsuitable for surgical revascularization or PTA. (Source: Journal of Translational Medicine)
Source: Journal of Translational Medicine - April 17, 2014 Category: Research Authors: Jiunn-Jye SheuPao-Yuan LinPei-Hsun SungYi-Ching ChenSteve LeuYung-Lung ChenTzu-Hsien TsaiHan-Tan ChaiSarah ChuaHsueh-Wen ChangSheng-Ying ChungChih-Hung ChenSheung-Fat KoHon-Kan Yip Source Type: research

Cilostazol induces mitochondrial fatty acid β-oxidation in C2C12 myotubes.
In this study, we report that cilostazol can elevate complete FAO and decrease both triacylglycerol (TAG) accumulation and TAG secretion. This use of cilostazol treatment increases expression of PGC-1α and, subsequently, its target genes, such as ERRα, NOR1, CD36, CPT1, MCAD, and ACO. Expression of these factors is linked to fatty acid β-oxidation but this effect is inhibited by H-89, a specific inhibitor of the PKA/CREB pathway. Importantly, knockdown of PGC-1α using siRNA abolished the effects of cilostazol in fatty acid oxidation (FAO) and TAG metabolism. These findings suggested that the PKA/CREB/PGC-1α pathway pl...
Source: Biochemical and Biophysical Research communications - April 11, 2014 Category: Biochemistry Authors: Wang B, Zhu L, Sui S, Sun C, Jiang H, Ren D Tags: Biochem Biophys Res Commun Source Type: research

Colonic diverticular hemorrhage associated with the use of NSAIDs, low‐dose aspirin, antiplatelet drugs, and dual therapy
ConclusionsBesides alcohol and smoking, NSAIDs, low‐dose aspirin, and antiplatelet drugs are risk factors for diverticular bleeding. The magnitude of risk may differ between different kinds of NSAIDs and antiplatelet drugs, and dual therapy with NSAIDs or antiplatelet drugs increases the risk of bleeding. (Source: Journal of Gastroenterology and Hepatology)
Source: Journal of Gastroenterology and Hepatology - April 10, 2014 Category: Gastroenterology Authors: Naoyoshi Nagata, Ryota Niikura, Tomonori Aoki, Takuro Shimbo, Yoshihiro Kishida, Katsunori Sekine, Shohei Tanaka, Kazuhiro Watanabe, Toshiyuki Sakurai, Chizu Yokoi, Junichi Akiyama, Mikio Yanase, Masashi Mizokami, Naomi Uemura Tags: Clinical Gastroenterology Source Type: research

Cilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation.
Conclusions: Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking. PMID: 24694769 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - April 3, 2014 Category: Cardiology Authors: Kim HL, Suh JW, Lee SP, Kang HJ, Koo BK, Cho YS, Youn TJ, Chae IH, Choi DJ, Rha SW, Bae JH, Kwon TG, Bae JW, Cho MC, Kim HS Tags: Circ J Source Type: research

CILOSTAZOL Tablet [BIOKEY INC.]
Updated Date: Apr 1, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))
Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST) - April 1, 2014 Category: Drugs & Pharmacology Source Type: news

Long-term niacin treatment induces insulin resistance and adrenergic responsiveness in adipocytes by adaptive downregulation of phosphodiesterase 3B
The lipid-lowering effect of niacin has been attributed to the inhibition of cAMP production in adipocytes, thereby inhibiting intracellular lipolysis and release of nonesterified fatty acids (NEFA) to the circulation. However, long-term niacin treatment leads to a normalization of plasma NEFA levels and induces insulin resistance, for which the underlying mechanisms are poorly understood. The current study addressed the effects of long-term niacin treatment on insulin-mediated inhibition of adipocyte lipolysis and focused on the regulation of cAMP levels. APOE*3-Leiden.CETP transgenic mice treated with niacin for 15 wk we...
Source: AJP: Endocrinology and Metabolism - April 1, 2014 Category: Endocrinology Authors: Heemskerk, M. M., van den Berg, S. A. A., Pronk, A. C. M., van Klinken, J.-B., Boon, M. R., Havekes, L. M., Rensen, P. C. N., van Dijk, K. W., van Harmelen, V. Tags: Articles Source Type: research

Cilostazol reduces morbidity but not mortality secondary to cerebral vasospasm following aneurysmal subarachnoid hemorrhage
I have read, with great interest, a recently published article in the Journal of the Neurological Sciences by Niu et al. titled ‘Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: A systematic review and meta-analysis’ . In this meta-analysis, the authors analyze the outcomes for 340 patients from four studies (two randomized and two quasi-randomized controlled trials) which evaluated the effect of cilostazol, a phosphodiesterase inhibitor 3 (PDE3) inhibitor, on cerebral vasospasm (CV) and overall outcomes following aneurysmal subarachnoid hemorrhage (aSAH). The total numbers of patients in the c...
Source: Journal of the Neurological Sciences - March 31, 2014 Category: Neurology Authors: Dale Ding Tags: Letters to the Editor Source Type: research

Semi‐Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Antiplatelet Agents
We examined the relationships between plasma concentrations of antiplatelet agents (triflusal, clopidogrel and cilostazol) and the platelet aggregation inhibitory effect after dosing. We used triflusal, cilostazol and clopidogrel for the development of a semi‐mechanistic PK/PD model. The drugs chosen are used widely and reflect various mechanisms of antiplatelet agents. Time courses of plasma concentrations of the antiplatelet agents and their platelet aggregation effects were analysed using ADPAT V. Pharmacokinetic profiles were fitted to an extended parent–metabolite pharmacokinetic model, based on a two‐compartmen...
Source: Basic and Clinical Pharmacology and Toxicology - March 29, 2014 Category: Drugs & Pharmacology Authors: Hwi‐yeol Yun, Wonku Kang, Byung‐yo Lee, Sunkyung Park, Young‐Ran Yoon, Jin Yeul Ma, Kwang‐il Kwon Tags: Original Article Source Type: research

Healthcare Quality Indicators of Peripheral Artery Disease Based on Systematic Reviews.
CONCLUSIONS: These quality indicators will help clinicians to assess the appropriateness of healthcare provided in PAD. The development of evidence-based indicators in PAD is limited by the lack of methodological quality of the research in this disease, the inconclusiveness of the evidence on diagnostic and surgical techniques, and the dynamic nature of the vascular diseases field. PMID: 24650396 [PubMed - as supplied by publisher] (Source: PubMed: Eur J Vasc Endovasc ...)
Source: PubMed: Eur J Vasc Endovasc ... - March 17, 2014 Category: Surgery Authors: Bellmunt S, Roqué M, Osorio D, Pardo H, Escudero JR, Bonfill X Tags: Eur J Vasc Endovasc Surg Source Type: research

Effect of Cilostazol Prescribed in a Pragmatic Treatment Program for Intermittent Claudication
Conclusion: Despite minimal behavior modification, up to 70% of patients taking cilostazol report an improvement in claudication symptoms with few side effects. (Source: Vascular and Endovascular Surgery)
Source: Vascular and Endovascular Surgery - March 5, 2014 Category: Surgery Authors: Lee, C., Nelson, P. R. Tags: Articles Source Type: research

Effects of Chronic Treatment With Cilostazol, a Phosphodiesterase 3 Inhibitor, on Female Rat Bladder in a Partial Bladder Outlet Obstruction Model
Conclusion: PDE3i has a small but significant protective effect on the contractile dysfunction induced by a 4-week BOO in rats, although the increase in bladder mass was not altered. PDE3i could be a useful protection against contractile dysfunction of the obstructed bladder. (Source: Urology)
Source: Urology - February 27, 2014 Category: Urology & Nephrology Authors: Seiji Matsumoto, Masaki Watanabe, Kazumi Hashizume, Naoki Wada, Jun-ichi Hori, Masafumi Kita, Tatsuya Iwata, Hidehiro Kakizaki Tags: Basic and Translational Science Source Type: research

Semi‐Mechanistic Modelling and Simulation of Inhibition of Platelet Aggregation by Anti‐Platelet Agents
This article is protected by copyright. All rights reserved. (Source: Basic and Clinical Pharmacology and Toxicology)
Source: Basic and Clinical Pharmacology and Toxicology - February 24, 2014 Category: Drugs & Pharmacology Authors: Hwi‐yeol Yun, Wonku Kang, Byung‐yo Lee, Sunkyung Park, Young‐Ran Yoon, Kwang‐il Kwon Tags: Original Article Source Type: research

Homocysteine as a Predictor of Early Neurological Deterioration in Acute Ischemic Stroke [Brief Reports]
Conclusions— Patients with acute stroke with elevated serum homocysteine levels are at an increased risk for END. (Source: Stroke)
Source: Stroke - February 24, 2014 Category: Neurology Authors: Kwon, H.-M., Lee, Y.-S., Bae, H.-J., Kang, D.-W. Tags: Risk Factors, Epidemiology Brief Reports Source Type: research